Reduce trial and error antidepressant prescribing.

Introducing the second generation pharmacogenetic report.

We recognise the frustrating reality of trial and error antidepressant prescribing. Data shows 30—50% of depressed patients do not respond to their first medication. Antidepressant remission rates are lower than those for response at 37.5%. The good news is CNSDose significantly increases remission rates.

Up to 50% of depressed patients do not respond to their first medication

Antidepressant remission rates are lower than those for response at 37.5%

RCT evidence shows gene guidance
doubles remission.

Our Randomised Controlled Trial (RCT) of 148 patients with DSM-5 defined Major Depressive Disorder (MDD) found a remission rate of 72% for genetically guided dosing versus 28% for genetically unguided dosing. Our number needed to genotype was 3, to produce an additional remission. This equates to level 1b evidence (Oxford System for Evidence-Based Medicine). We also have a tenure-track academic-led concordance study completed, publication anticipated by mid-2016.

Gene Guidance remission rate %

Use the keys to the blood brain barrier.

Our product is the first-in-case using this technology. Our system analyses two key pharmacokinetic steps governing antidepressant central nervous system (CNS) bioavailability − hepatic metabolism enzyme system (CYP450 & UGT1A1) and the active efflux transporters (ABC transporters) at the Blood Brain Barrier.

Simple, fast, personalized results stored in the cloud.

Your patient can send their saliva sample to one of our affiliated labs. Once analysis is completed, you will receive an easy to use CNSDose Report providing guidance on appropriate medications and dosing suggestions.